stock
MTRI · InMed Pharmaceuticals Inc.
Insiders net bought $34,572 in 90 days; last 8-K filed Nov 16: acquisition or sale completed, results.
Follow MTRI freePrice
Loading the MTRI chart…
Chart by TradingView
The business
What the company does and what it reports, from its SEC filings.
What it is
We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs.
From the 10-K for the fiscal year ended Jun 30, 2026, filed Sep 9, 2026.
Read the 10-K on SEC- Sector
- Life Sciences (SEC office)
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Employees
- Not stated in the 10-K.
- Headquarters
- Vancouver
- Incorporated in
- British Columbia, Canada
- Fiscal year ends
- June
- Exchange
- Nasdaq
- Fractional shares
- No
- Listed options
- No
- Filer category
- <br>Emerging growth company
- Shares outstanding
- 5,493,735 as of Oct 30, 2026 (XBRL frame )
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation and the ratios that use the live price are free with an account.
Start free to see thisDeep value
- NCAV
- -$1.24M
- NCAV per share
- -$0.23
- NNWC
- -$1.41M
- NNWC per share
- -$0.26
Expectations
- Free cash flow
- —
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- —
Margins
- Gross
- 29.7%
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- -1008.1%
Health
- Current ratio
- —
- Debt/equity
- —
Trailing twelve months to Sep 30, 2026; balance sheet at Sep 30, 2026.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| Sep 30, 2026 | — | — | — | -$2.33M | |
| Jun 30, 2026 | — | — | — | -$5.84M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| Mar 31, 2026 | — | — | — | -$2.97M | |
| Dec 31, 2025 | $820,188 | $184,194 | — | -$2.03M | Assembled from more than one filing; the filing above is only the newest of them. |
| Sep 30, 2025 | $1.12M | $403,159 | — | -$1.73M | Assembled from more than one filing; the filing above is only the newest of them. |
| Jun 30, 2025 | $1.30M | $576,654 | — | $4.67M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| Mar 31, 2025 | $1.26M | $175,625 | — | -$2.12M | Assembled from more than one filing; the filing above is only the newest of them. |
| Dec 31, 2024 | $1.11M | $460,894 | — | -$2.58M | Assembled from more than one filing; the filing above is only the newest of them. |
- Cash
- $1.09M
- Debt
- —
- Net cash
- —
- Current assets
- $1.26M
- Current liabilities
- —
- Working capital
- —
- Total liabilities
- $2.51M
- Assets
- $1.31M
- Equity
- -$1.20M
Balance as of Sep 30, 2026.
SEC data as of Nov 17, 2026
Earnings moves
| Report | Reaction day |
|---|---|
| Nov 16, 2026 Before the open | Nov 16, 2026 |
How the price moved after each report: Start free to see this
What happened after past reports, not a forecast. Report dates from SEC 8-K results filings (Item 2.02) since Oct 6, 2025; moves from daily closes.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| Jun 30, 2026 | — | — | -$12.56M | — |
| Jun 30, 2025 | $4.94M | — | -$1.70M | -$8.10M |
| Jun 30, 2024 | $4.60M | — | -$7.68M | -$7.00M |
| Jun 30, 2023 | $1.37M | -$7.95M | -$7.95M | -$7.44M |
| Jun 30, 2022 | $1.37M | -$18.60M | -$18.60M | -$15.62M |
| Jun 30, 2021 | $1.90M | -$10.20M | -$10.20M | -$9.79M |
| Jun 30, 2020 | — | — | -$8.94M | -$7.42M |
What it filed
Material events and 5% ownership filings from the last year.
Company filings
since Fri Mar 20 · 3 offering filings in 12 months · since Fri Apr 3
events
- Acquisition or sale completedResultsNov 168-K
- Material agreementAcquisition or sale completedResultsUnregistered share saleShareholder rights changedChange in controlExecutive or director changeBylaws or fiscal year changeItem 5.05Item 5.06
CEO succession, abrupt
Nov 108-K - Regulation FD disclosureNov 98-K
- Regulation FD disclosureNov 58-K
- Bylaws or fiscal year changeShareholder vote resultsOther eventNov 58-K
- Regulation FD disclosureNov 38-K
5% owners ()
Squadron Master Fund LP
Stake update
Commodore Capital LP
Passive stake
Deep Track Capital, LP
Passive stake
Fairmount Funds Management LLC
Activist stake
ADAR1 Capital Management, LLC
Stake update
Owners and trading
Insider, politician and fund moves, short interest, and the volume traded off the exchange.
Insiders, politicians and funds
Insider trades, last 90 days
ADAR1 Capital Management, LLC
10% owner
Buy$34,572Nov 9, 8:18 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Hard to borrow: Alpaca will not lend it for shorting
Off-exchange short volume, 20 days
28.7%
Through Nov 16, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
Off-exchange and dark pools
No off-exchange data
Members see
- Signals: which strategies fired on MTRI, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- Earnings moves: how the price moved after each report
- News: stories counted once across outlets
nakagai
Signals on MTRI come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow MTRI free
Comments · 0
No comments yet.